Comparable stake leader
Ebrahim Versi
SEC ownership of DMK PHARMACEUTICALS Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000887247.
Disclosed value leader
Ebrahim Versi
Comparable rows
0/11
Latest evidence
23 Oct 2023
- Parsed ownership sources
- 3/4/5
- Largest SEC-reported holder
- Ebrahim Versi
- Latest parsed ownership date
- 23 Oct 2023
- Issuer CIK
- 0000887247
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of DMK PHARMACEUTICALS Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ebrahim Versi
Disclosed value leader
Ebrahim Versi
Comparable rows
0/11
Latest evidence
23 Oct 2023
3/4/5
Highest disclosed value: $552,377
11 rows are not safely comparable across share classes.
Showing 1-8 of 11 holder rows.
Quick read
Ebrahim Versi has the largest disclosed position value at $552.4K.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ebrahim Versi's linked filing trail.
Disclosed position value
Top 5
Ebrahim Versi
$552.4K
Dennis J. Carlo PhD
$418K
David J. Marguglio
$144.7K
Ronald B. Moss
$121.9K
Jannine Versi
$107K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ebrahim Versi |
3/4/5
CEO, Director
|
—
mixed-class rows
|
$552,377
916,351 shares
mixed-class rows
|
— | 15 Sep 2023 |
| Dennis J. Carlo PhD |
3/4/5
Former President & CEO
|
—
class O/S missing
|
$417,968
692,459 shares
|
— | 25 May 2022 |
| David J. Marguglio |
3/4/5
SVP and Chief Business Officer, Director
|
—
class O/S missing
|
$144,738
239,790 shares
|
— | 18 Mar 2022 |
| Ronald B. Moss |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$121,873
201,911 shares
|
— | 18 Mar 2022 |
| Jannine Versi |
3/4/5
Director
|
—
mixed-class rows
|
$106,954
184,279 shares
mixed-class rows
|
— | 25 May 2023 |
| David C. Benedicto |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$24,069
39,875 shares
|
— | 18 Mar 2022 |
| Meera J. Desai |
3/4/5
Director
|
—
class O/S missing
|
$1,894
3,138 shares
|
— | 25 May 2023 |
| Seth Cohen |
3/4/5
CFO
|
—
class O/S missing
|
—
151,416 shares
|
— | 16 Oct 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to DMK PHARMACEUTICALS Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Ebrahim Versi
Net 12M change
$0
Latest report
23 Oct 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ebrahim Versi | CEO, Director | $552,377 | Mixed | 15 Sep 2023 | ||
| Dennis J. Carlo PhD | Former President & CEO | $417,968 | Mixed | 25 May 2022 | ||
| David J. Marguglio | SVP and Chief Business Officer, Director | $144,738 | Mixed | 18 Mar 2022 | ||
| Ronald B. Moss | Chief Medical Officer | $121,873 | Filing P/S | 18 Mar 2022 | ||
| Jannine Versi | Director | $106,954 | Mixed | 25 May 2023 | ||
| David C. Benedicto | Chief Financial Officer | $24,069 | Filing P/S | 18 Mar 2022 | ||
| Meera J. Desai | Director | $1,894 | Mixed | 25 May 2023 | ||
| Vickie S. Reed | Director | Mixed | 24 May 2022 | |||
| Howard C. Birndorf | Director | Mixed | 14 Nov 2022 | |||
| Seth Cohen | Cfo | Mixed | 16 Oct 2023 | |||
| John W. Dorbin Jr. | General Counsel | Mixed | 23 Oct 2023 |
Recent insider transactions for DMK PHARMACEUTICALS Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.